Weekly Sepsis Research Analysis
This week’s sepsis literature highlights mechanistic host–microbiome and immunometabolic discoveries and promising translational interventions. A Journal of Clinical Investigation study delineated a hepcidin–gut microbiome (IPA/Lactobacillus)–Kupffer cell axis that preserves hepatic bacterial capture. Two complementary high-impact reports reveal host-directed control points for immunothrombosis/NETosis (Acod1/itaconate→UBR5→PAD4) and translational validation of factor XI inhibition (abelacimab)
Summary
This week’s sepsis literature highlights mechanistic host–microbiome and immunometabolic discoveries and promising translational interventions. A Journal of Clinical Investigation study delineated a hepcidin–gut microbiome (IPA/Lactobacillus)–Kupffer cell axis that preserves hepatic bacterial capture. Two complementary high-impact reports reveal host-directed control points for immunothrombosis/NETosis (Acod1/itaconate→UBR5→PAD4) and translational validation of factor XI inhibition (abelacimab) improving survival in a primate sepsis model. Rapid diagnostics (direct MALDI-TOF) and prognostic tools (lactylation gene signature, EV 5hmC) further enable earlier, targeted management.
Selected Articles
1. Hepcidin sustains Kupffer cell immune defense against bloodstream bacterial infection via gut-derived metabolites in mice.
Using gnotobiotic manipulation, fecal transfer, metabolite rescue, and clinical correlations, this study shows hepcidin deficiency reduces an IPA-producing commensal (Lactobacillus intestinalis), diminishes gut-to-liver IPA shuttling, alters Kupffer cell morphology/volume, and impairs bacterial capture, promoting dissemination. IPA supplementation or L. intestinalis colonization restored Kupffer cell function; hepcidin levels in bacteremic patients correlated with antibiotic days and hospitalization.
Impact: Reveals a microbiome-dependent hepcidin–IPA–Kupffer cell axis that mechanistically sustains hepatic capture and clearance of bloodstream bacteria, opening host-directed strategies (microbiome or metabolite augmentation) to reduce dissemination.
Clinical Implications: Phenotyping low-hepcidin states in bacteremic/septic patients could identify candidates for microbiome or IPA augmentation to enhance hepatic bacterial clearance; informs biomarker development and potential adjunctive therapies.
Key Findings
- Hepcidin deficiency reduced Lactobacillus intestinalis abundance and gut-to-liver shuttling of indole-3-propionic acid (IPA).
- Hepcidin loss altered Kupffer cell morphology/volume and impaired bacterial capture, increasing dissemination.
- IPA supplementation or L. intestinalis colonization restored Kupffer cell function and hepatic defense.
- In bacteremic patients, hepcidin levels correlated with antibiotic days and hospitalization duration.
2. Acod1 Promotes PAD4 Ubiquitination via UBR5 Alkylation to Modulate NETosis and Exert Protective Effects in Sepsis.
This multi-omics and genetic study identifies an Acod1/itaconate→UBR5 alkylation mechanism that promotes K48-linked ubiquitination and degradation of PAD4, thereby suppressing NETosis. Acod1 knockout increased NETs, inflammation, organ injury, and mortality in CLP models, positioning the Acod1–UBR5–PAD4 axis as a druggable immunometabolic control point.
Impact: Uncovers a novel immunometabolic–ubiquitin pathway that directly controls NETosis and links metabolism (itaconate) to PAD4 turnover—identifying mechanistic, druggable nodes (UBR5, PAD4) for reducing NET-mediated damage in sepsis.
Clinical Implications: Supports development of strategies to boost Acod1/itaconate signaling or pharmacologically modulate UBR5–PAD4 interactions to limit NETosis-related organ injury; suggests NET-focused biomarkers to stratify patients for such therapies.
Key Findings
- NET levels rose in sepsis patients and CLP mice and correlated with Acod1 expression.
- Acod1 knockout worsened NETosis, inflammation, organ injury, and survival in CLP models.
- Acod1/itaconate alkylated and activated UBR5, promoting PAD4 K48-linked ubiquitination and degradation to suppress NETosis.
3. Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis.
In a randomized baboon S. aureus sepsis model, abelacimab (FXI inhibitor) produced 100% 7-day survival versus 50% mortality in controls, attenuated sepsis-induced coagulopathy without bleeding, reduced proinflammatory cytokines and neutrophil activation, preserved endothelial integrity, and modulated proteomic signatures linked to coagulation, inflammation, and tissue injury.
Impact: Provides strong translational nonhuman primate evidence that FXI inhibition can improve survival and mitigate immunothrombosis and organ injury in sepsis while avoiding bleeding—directly motivating early-phase clinical evaluation.
Clinical Implications: Supports prioritizing early-phase clinical trials of FXI inhibitors (e.g., abelacimab) in sepsis to test safety, dosing, and efficacy for reducing immunothrombosis and organ failure with a favorable bleeding profile.
Key Findings
- Abelacimab-treated baboons (n=6) all survived to day 7; 3/6 controls died within ~102 hours.
- FXI inhibition attenuated coagulopathy without causing bleeding and reduced inflammatory/neutrophil activation markers.
- Proteomics indicated modulation of coagulation, inflammation, and tissue-injury pathways consistent with organ protection.